Semin Thromb Hemost 2000; 26(5): 495-502
DOI: 10.1055/s-2000-13205
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Impaired Endogenous Fibrinolysis in Diabetes Mellitus: Mechanisms and Therapeutic Approaches

Thomas K. Nordt, Christoph Bode
  • Department of Cardiology, University of Freiburg, Germany
Further Information

Publication History

Publication Date:
31 December 2000 (online)

ABSTRACT

In type II diabetes mellitus the activity of the endogenous fibrinolytic system is reduced secondary to increased plasma activity of the plasminogen activator inhibitor type 1 (PAI-1). Because PAI-1 is considered an independent risk factor for cardiovascular disease, increased PAI-1 activity in diabetes mellitus may partly explain the increased susceptibility to both primary atherosclerosis and restenosis after angioplasty in this disease. The factors contributing to increased PAI-1 expression in diabetes mellitus are reviewed as well as possible therapeutic approaches to normalize increased PAI-1 expression.

REFERENCES

  • 1 Andreotti F, Davies G J, Hackett D R. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardic death and stroke.  Am J Cardiol . 1988;  62 635-637
  • 2 Angleton P, Chandler W L, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).  Circulation . 1989;  79 101-106
  • 3 Krishnamurti C, Barr C F, Hassett M A, Young G D, Alving B M. Plasminogen activator inhibitor: A regulator of ancrod-induced fibrin deposition in rabbits.  Blood . 1987;  69 798-803
  • 4 Vaughan D E, Declerck P J, van Houtte E, de Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.  Thromb Haemost . 1992;  68 60-63
  • 5 Levi M, Biemond B J, van Zonneveld J A, Wouter ten Cate J, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis.  Circulation . 1992;  85 305-312
  • 6 Erickson L A, Fici G J, Lund J E. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene.  Nature . 1990;  346 74-76
  • 7 Carmeliet P, Stassen J M, Schoonjans L. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.  J Clin Invest . 1993;  92 2756-2760
  • 8 Reilly C F, Fujita T, Hutzelmann J E, Mayer E J, Shebuski R J. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.  Circulation . 1991;  84 287-292
  • 9 Aznar J, Estellés A, Tormo G. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.  Br Heart J . 1988;  59 535-541
  • 10 Olofsson B O, Dahlén G, Nilsson T K. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.  Eur Heart J . 1989;  10 77-82
  • 11 Huber K, Jörg M, Probst P. A decrease in plasminogen activator-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis.  Thromb Haemost . 1992;  67 209-213
  • 12 Verheugt F WA, ten Cate W J, Sturk A. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries.  Am J Cardiol . 1987;  59 1075-1079
  • 13 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.  N Engl J Med . 1985;  313 1557-1563
  • 14 Hamsten A, de Faire U, Waldius G. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction.  Lancet . 1987;  2 3-8
  • 15 Salomaa V, Stinson V, Kark J D. Association of fibrinolytic parameters with early atherosclerosis. The ARIC study.  Circulation . 1995;  91 284-290
  • 16 Cortellaro M, Cofrancesco E, Boschetti C. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study.  Arterioscler Thromb . 1993;  13 1412-1417
  • 17 Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease.  Semin Thromb Hemost . 1990;  16 207-216
  • 18 Grimaudo V, Bachmann F, Hauert J, Christe M A, Kruithof E KO. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.  Thromb Haemost . 1992;  67 397-401
  • 19 Barbash G I, Hod H, Roth A. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction.  Am J Cardiol . 1989;  64 1231-1235
  • 20 Sane D C, Stump D C, Topol E J. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction.  Thromb Haemost . 1991;  65 275-279
  • 21 Nordt T K, Moser M, Kohler B. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.  Thromb Haemost . 1998;  80 881-886
  • 22 Schleef R R, Higgins D L, Pillemer E, Levitt L J. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.  J Clin Invest . 1989;  83 1747-1752
  • 23 Diéval J, Nguyen G, Gross S, Delobel J, Kruithof E KO. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.  Blood . 1991;  77 528-532
  • 24 Fay W P, Shapiro A D, Shih J L, Schleef R R, Ginsburg D. Complete deficiency of plasminogen activator inhibitor type 1 due to a frame-shift mutation.  N Engl J Med . 1992;  327 1729-1733
  • 25 Lee M H, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.  Blood . 1993;  81 2357-2362
  • 26 Nordt T K, Peter K, Ruef J, Kübler W, Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease.  Thromb Haemost . 1999;  82(Suppl) 14-18
  • 27 Factor S M, Segal B H, van Hoeven H K. Diabetes and coronary artery disease.  Coronary Artery Dis . 1992;  3 4-10
  • 28 Califf R M, Fortin D F, Frid D J. Restenosis after coronary angioplasty: An overview.  J Am Coll Cardiol . 1991;  17 2B-13B
  • 29 Sobel B E. Potentiation of vasculopathy by insulin: Implications from an NHLBI Clinical Alert.  Circulation . 1996;  93 1613-1615
  • 30 The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease.  N Engl J Med . 1996;  335 217-225
  • 31 Juhan-Vague I, Alessi M C, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.  Diabetologia . 1991;  34 457-462
  • 32 Schneider D J, Nordt T K, Sobel B E. Attenuated fibrinolysis and accelerated atherosclerosis in type II diabetic patients.  Diabetes . 1993;  42 1-7
  • 33 Falk E, Shah P K, Fuster V. Coronary plaque disruption.  Circulation . 1995;  92 657-671
  • 34 Bakker C M, Metselaar H J, Groenland T N. Increased tissue-type plasminogen activator activity in orthotopic but not heterotopic liver transplantation: The role of the anhepatic period.  Hepatology . 1992;  16 404-408
  • 35 Kooistra T. The use of cultured human endothelial cells and hepatocytes as an in vitro model system to study modulation of endogenous fibrinolysis.  Fibrinolysis . 1990;  4(Suppl 2) 33-39
  • 36 Maiello M, Boeri D, Podesta F. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose.  Diabetes . 1992;  41 1009-1015
  • 37 Cagliero E, Roth T, Roy S, Maiello M, Lorenzi M. Expression of genes related to the extracellular matrix in human endothelial cells.  J Biol Chem . 1991;  266 14244-14250
  • 38 Nordt T K, Klassen K J, Schneider D J, Sobel B E. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.  Arterioscler Thromb . 1993;  13 1822-1828
  • 39 Hughes H H. Swine in cardiovascular research.  Lab Anim Sci . 1986;  36 348-350
  • 40 van Hinsbergh W M V, Binnema D, Scheffer M A. Production of plasminogen activators and inhibitor by serially propagated endothelial cells from adult human blood vessels.  Arteriosclerosis . 1987;  7 389-400
  • 41 Nordt T K, Schneider D J, Sobel B E. Augmentation of the synthesis of plasminogen activator inhibitor type-1 (PAI-1) by precursors of insulin: A potential risk factor for vascular disease.  Circulation . 1994;  89 321-330
  • 42 Sobey W J, Beer S F, Carrington C A. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins.  Biochem J . 1989;  260 535-541
  • 43 Bowsher R R, Wolny J D, Frank B H. A rapid and sensitive radioimmunoassay for the measurement of proinsulin in human serum.  Diabetes . 1992;  41 1084-1090
  • 44 Temple R C, Clark P MS, Nagi D K. Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics.  Clin Endocrinol . 1990;  32 689-693
  • 45 Nagi D K, Hendra T J, Ryle A J. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects.  Diabetologia . 1990;  33 532-537
  • 46 Heding L G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients.  Diabetologia . 1972;  8 260-266
  • 47 Alessi M C, Juhan-Vague I, Kooistra T, Declerck P J, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2.  Thromb Haemost . 1988;  60 491-494
  • 48 Kooistra T, Bosma P J, Töns H AM. Plasminogen activator inhibitor 1: Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes.  Thromb Haemost . 1989;  62 123-128
  • 49 Schneider D J, Sobel B E. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states.  Proc Natl Acad Sci USA . 1991;  88 9959-9963
  • 50 Spradlin C T, Galloway J A, Anderson J H. Apparent increase in coronary heart disease with human proinsulin (HPI): Randomization failure or HPI effect?.  Diabetologia . 1990;  33(Suppl) A60
  • 51 Galloway J A, Hooper S A, Spradlin C T. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience.  Diabetes Care . 1992;  15 666-692
  • 52 Jain S K, Nagi D K, Slavin B M, Lumb P J, Yudkin J S. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) avtivity and proinsulin-like molecules independently of glycemic control.  Diabetic Med . 1993;  10 27-32
  • 53 Misbin R I, Merimee T J, Lowenstein J M. Insulin removal by isolated perfused rat liver.  Am J Physiol . 1976;  230 171-177
  • 54 Glauber H S, Henry R R, Wallace P. The effects of biosynthetic human proinsulin on carbohydrate metabolism in non-insulin-dependent diabetes mellitus.  N Engl J Med . 1987;  316 443-449
  • 55 Nordt T K, Sawa H, Fujii S, Sobel B E. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.  Circulation . 1995;  91 764-770
  • 56 Fujii S, Sobel B E. Induction of plasminogen activator inhibitor by products released from platelets.  Circulation . 1990;  82 1485-1493
  • 57 Nordt T K, Sawa H, Fujii S, Sobel B E. Hyperinsulinemia increases plasma activity of PAI-1 in vivo independently of an acute phase reaction.  Fibrinolysis . 1997;  11(Suppl 1) 51-54
  • 58 Nordt T K, Sawa H, Fujii S, Bode C, Sobel B E. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo.  J Mol Cell Cardiol . 1998;  30 1535-1543
  • 59 Grant P J, Kruithof E KO, Felley C P, Felber J P, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 conmcentratiosn in man.  Clin Sci . 1990;  79 513-516
  • 60 Landin K, Tengborn L, Chmielewska J, von Schenck H, Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man.  Thromb Haemost . 1991;  65 130-133
  • 61 Vuorinen-Markkola H, Puhakainen I, Yki-Järvinen H. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man.  Thromb Haemost . 1992;  67 117-120
  • 62 Potter van Loon J B, de Bart C W A, Radder J K. Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans.  Fibrinolysis . 1990;  4(Suppl 2) 93-94
  • 63 Frick M H, Elo O, Haapa K. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.  N Engl J Med . 1987;  317 1237-1245.
  • 64 Manninen V, Elo M O, Frick M H. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.  JAMA . 1988;  260 641-651
  • 65 Tenkanen L, Mänttäri M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study.  Circulation . 1995;  92 1779-1785
  • 66 Huttunen J K, Heinonen O P, Manninen V. The Helsinki Heart Study: An 8.5-year safety and mortality follow-up.  J Intern Med . 1994;  235 31-39
  • 67 Avellone G, Di Garbo V, Panno A V. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia.  Int Angiol . 1988;  7 270-277
  • 68 Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction.  Thromb Haemost . 1990;  63 174-177
  • 69 Nordt T K, Kornas K, Peter K. Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type-1 induced by insulin and its precursors.  Circulation . 1997;  95 677-683
  • 70 Nilsson L, Takemura T, Eriksson P, Hamsten A. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.  Arterioscler Thromb Vasc Biol . 1999;  19 1577-1581
  • 71 Keber I, Lavre J, Suc S, Keber D. The decrease of plasminogen activator inhibitor after normalization of triglycerides during treatment with fibrates.  Fibrinolysis . 1994;  8(Suppl 2) 57-59
  • 72 Bröijersen A, Eriksson M, Wiman B, Angelin B, Hjemdahl P. Gemfibrozil treatment of combined hyperlipoproteinemia.  No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arterioscler Thromb Vasc Biol . 1996;  16 511-516
  • 73 Cimminiello C, Vigorelli P, Piliego T. Fibrinolytic response in subjects with hypertriglyceridemia and low HDL cholesterol.  Biomed Pharmacother . 1997;  51 164-169
  • 74 Kockx M, de Maat P M M, Knipscheer H C. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidemic patients.  Thromb Haemost . 1997;  78 1167-1172
  • 75 Jeng J R, Jeng C Y, Sheu W H. Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance.  Am Heart J . 1997;  134 565-571
  • 76 Pazzucconi F, Mannucci L, Mussoni L. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridemia.  Eur J Clin Pharmacol . 1992;  43 219-223